8-K: Microbot Medical Aligns with AMA on Radiation Safety

Microbot Medical Inc. announced its LIBERTY Endovascular Robotic System aligns with a new American Medical Association policy aimed at protecting healthcare professionals from ionizing radiation.

Summary

• Microbot Medical Inc. issued a press release commending the American Medical Association's (AMA) efforts to protect healthcare professionals from ionizing radiation.
• The AMA adopted a new policy in late 2025 to strengthen protections, emphasizing research into cumulative exposure, PPE effectiveness, and education.
• Microbot's LIBERTY Endovascular Robotic System is remotely operated, enabling physicians and staff to perform procedures away from the radiation source.
• The ACCESS-PVI Study demonstrated a 92% relative reduction in radiation exposure when using the LIBERTY System.
• Prolonged radiation exposure contributes to health issues like cancer, cardiovascular disease, and staffing shortages in endovascular specialties, disproportionately affecting women.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
• The Company commenced a Limited Market Release (LMR) of the LIBERTY system in late 2025.
• A Full Market Release (FMR) is planned for the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strategically aligns Microbot Medical with a significant industry trend and regulatory body, potentially boosting market adoption and addressing key healthcare challenges.

Positives

• The LIBERTY Endovascular Robotic System aligns with a new American Medical Association (AMA) policy to protect healthcare professionals from ionizing radiation.
• The system's remote operation capability allows physicians and staff to avoid direct radiation exposure.
• The ACCESS-PVI Study showed a significant 92% relative reduction in radiation exposure when using LIBERTY.
• LIBERTY addresses critical issues like long-term health effects from radiation and staffing shortages in endovascular specialties.
• The system is FDA cleared, indicating regulatory approval for its use in peripheral endovascular procedures.
• The wireless operation reduces reliance on heavy Personal Protection Equipment (PPE) and lessens musculoskeletal strain for healthcare providers.

Risks

• Market conditions.
• Risks inherent in the commercialization of the LIBERTY Endovascular Robotic System.
• Risks in the development of future versions of or applications for the system.
• Uncertainty in the results of regulatory pathways and regulatory approvals.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA.
• Announcements of tariffs on imports into the U.S.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Maintenance of intellectual property rights.

Future Outlook

Microbot Medical plans for a Full Market Release (FMR) of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption. The company believes LIBERTY can play a major role in addressing challenges related to radiation exposure and staffing shortages, supporting better care for providers and patients.

Management Comments

• "Prolonged exposure to radiation and staffing shortages are rising concerns among healthcare professionals in the endovascular space."
• "We believe that these challenges strain an already overburdened health care system, impacting patient care, and widening the skills gap required to address the medical concerns."
• "We also believe that LIBERTY can play a major role in addressing these challenges and supporting better care for both providers and their patients."

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in robotics, is increasingly focused on improving safety and efficiency for healthcare professionals. The alignment with AMA's new policy on radiation protection positions Microbot Medical's LIBERTY system favorably within a growing market segment concerned with occupational health and staffing retention in interventional procedures. This move could enhance the company's reputation and market penetration by addressing a critical industry pain point.

Comparison to Industry Standards

• The 92% relative reduction in radiation exposure demonstrated by the LIBERTY System in the ACCESS-PVI Study is a significant improvement compared to traditional manual endovascular procedures, where physicians are directly exposed to ionizing radiation.
• The LIBERTY System's FDA clearance as the only single-use, remotely operated robotic system for peripheral endovascular procedures distinguishes it from other robotic systems that may not offer the same combination of remote operation, single-use design, or specific FDA clearance for this application.
• The system directly addresses the industry-wide concern of physician shortages in specialties like interventional radiology, which ranks number two among specialties with highest physician shortages, by mitigating factors like radiation exposure and physical strain that deter professionals, especially women.

Stakeholder Impact

• Shareholders: Potential for increased market adoption and revenue due to alignment with industry safety standards and addressing staffing shortages.
• Healthcare Professionals (Physicians/Staff): Reduced radiation exposure, lessened musculoskeletal strain, and improved working conditions.
• Patients: Potential for improved patient care due to reduced strain on the healthcare system and wider availability of skilled professionals.
• Hospitals/Healthcare Providers: Access to technology that enhances safety, potentially reduces staffing issues, and aligns with best practices.

Next Steps

• Full Market Release (FMR) of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepen market adoption of the LIBERTY system.
• Continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational risk (as emphasized by AMA policy).

Key Dates

Recommendation

The announcement is strategically positive, highlighting the LIBERTY system's alignment with a new AMA policy on radiation safety and its potential to address staffing shortages. This could drive future market adoption. However, without specific financial metrics or updated guidance, it's difficult to assess the immediate impact on revenue or profitability. The company is still in the early stages of its Full Market Release, and while the news is favorable, it doesn't warrant an immediate "buy" without further financial performance indicators. Investors should hold and monitor the success of the Full Market Release and subsequent financial reports.

Keywords

Microbot Medical, LIBERTY System, Endovascular Robotic System, Radiation Exposure, American Medical Association, AMA Policy, Healthcare Technology, Medical Device, FDA Cleared, Interventional Radiology, Robotic Surgery, Peripheral Endovascular Procedures